Platelet morphology and plasma indices of platelet activation in essential hypertension: Effects of amlodipine-based antihypertensive therapy

Sunil Nadar, Andrew D. Blann, Gregory Y H Lip

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

BACKGROUND AND AIM. Platelet abnormalities have been described in hypertension, especially in the presence of target organ damage. Our aim was to study the differences in morphology and indices of platelet activation in treatment-naive patients with essential hypertension as compared to normotensive controls and secondly, to study the effects of amlodipine-based antihypertensive therapy on these indices. METHODS. We recruited 42 previously untreated, newly diagnosed hypertensive patients (25 men; mean age 53 years) for the cross-sectional study, where data were compared with those from 30 normotensive controls (20 men; mean age 57 years). Of the 42 untreated hypertensive patients who were recruited, 27 patients successfully completed, the six-month treatment phase with amlodipine-based antihypertensive therapy. Platelet morphology (volume and mass) was quantified, and plasma markers of platelet activation (βTG and sPsel) measured in citrated plasma. The mass of P-selectin in each platelet (pPsel) was determined by lysing a fixed number of platelets and then determining the levels of P-selectin in the lysate. RESULTS. Hypertensive patients had significantly higher platelet volume (P = 0.01) and mass (P = 0.003), plasma βTG and sPsel, and pPsel levels (all P < 0.001) compared to the controls. After a mean treatment time of 6 months, there was a decrease in platelet volume (P < 0.001) and mass (P = 0.02), with lower pPsel, sPsel and BTG levels (all P < 0.001) compared to the untreated state. CONCLUSION. Treatment of uncomplicated essential hypertension using amlodipine-based anti-hypertensive therapy results in a reversal of the platelet morphology abnormalities and indices of platelet activation. This may contribute to a reduction in thrombosis-related complications seen in those whose blood pressure lowering is effective.

Original languageEnglish
Pages (from-to)552-557
Number of pages6
JournalAnnals of Medicine
Volume36
Issue number7
DOIs
Publication statusPublished - 2004

Fingerprint

Amlodipine
Platelet Activation
Antihypertensive Agents
Blood Platelets
P-Selectin
Therapeutics
Essential Hypertension
Platelet Count
Thrombosis
Cross-Sectional Studies
Blood Pressure
Hypertension

Keywords

  • Calcium channel blockers
  • Hypertension
  • Platelet activation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Platelet morphology and plasma indices of platelet activation in essential hypertension : Effects of amlodipine-based antihypertensive therapy. / Nadar, Sunil; Blann, Andrew D.; Lip, Gregory Y H.

In: Annals of Medicine, Vol. 36, No. 7, 2004, p. 552-557.

Research output: Contribution to journalArticle

@article{976e9a6e6013466ab089cacaefaf280f,
title = "Platelet morphology and plasma indices of platelet activation in essential hypertension: Effects of amlodipine-based antihypertensive therapy",
abstract = "BACKGROUND AND AIM. Platelet abnormalities have been described in hypertension, especially in the presence of target organ damage. Our aim was to study the differences in morphology and indices of platelet activation in treatment-naive patients with essential hypertension as compared to normotensive controls and secondly, to study the effects of amlodipine-based antihypertensive therapy on these indices. METHODS. We recruited 42 previously untreated, newly diagnosed hypertensive patients (25 men; mean age 53 years) for the cross-sectional study, where data were compared with those from 30 normotensive controls (20 men; mean age 57 years). Of the 42 untreated hypertensive patients who were recruited, 27 patients successfully completed, the six-month treatment phase with amlodipine-based antihypertensive therapy. Platelet morphology (volume and mass) was quantified, and plasma markers of platelet activation (βTG and sPsel) measured in citrated plasma. The mass of P-selectin in each platelet (pPsel) was determined by lysing a fixed number of platelets and then determining the levels of P-selectin in the lysate. RESULTS. Hypertensive patients had significantly higher platelet volume (P = 0.01) and mass (P = 0.003), plasma βTG and sPsel, and pPsel levels (all P < 0.001) compared to the controls. After a mean treatment time of 6 months, there was a decrease in platelet volume (P < 0.001) and mass (P = 0.02), with lower pPsel, sPsel and BTG levels (all P < 0.001) compared to the untreated state. CONCLUSION. Treatment of uncomplicated essential hypertension using amlodipine-based anti-hypertensive therapy results in a reversal of the platelet morphology abnormalities and indices of platelet activation. This may contribute to a reduction in thrombosis-related complications seen in those whose blood pressure lowering is effective.",
keywords = "Calcium channel blockers, Hypertension, Platelet activation",
author = "Sunil Nadar and Blann, {Andrew D.} and Lip, {Gregory Y H}",
year = "2004",
doi = "10.1080/07853890410017386",
language = "English",
volume = "36",
pages = "552--557",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Platelet morphology and plasma indices of platelet activation in essential hypertension

T2 - Effects of amlodipine-based antihypertensive therapy

AU - Nadar, Sunil

AU - Blann, Andrew D.

AU - Lip, Gregory Y H

PY - 2004

Y1 - 2004

N2 - BACKGROUND AND AIM. Platelet abnormalities have been described in hypertension, especially in the presence of target organ damage. Our aim was to study the differences in morphology and indices of platelet activation in treatment-naive patients with essential hypertension as compared to normotensive controls and secondly, to study the effects of amlodipine-based antihypertensive therapy on these indices. METHODS. We recruited 42 previously untreated, newly diagnosed hypertensive patients (25 men; mean age 53 years) for the cross-sectional study, where data were compared with those from 30 normotensive controls (20 men; mean age 57 years). Of the 42 untreated hypertensive patients who were recruited, 27 patients successfully completed, the six-month treatment phase with amlodipine-based antihypertensive therapy. Platelet morphology (volume and mass) was quantified, and plasma markers of platelet activation (βTG and sPsel) measured in citrated plasma. The mass of P-selectin in each platelet (pPsel) was determined by lysing a fixed number of platelets and then determining the levels of P-selectin in the lysate. RESULTS. Hypertensive patients had significantly higher platelet volume (P = 0.01) and mass (P = 0.003), plasma βTG and sPsel, and pPsel levels (all P < 0.001) compared to the controls. After a mean treatment time of 6 months, there was a decrease in platelet volume (P < 0.001) and mass (P = 0.02), with lower pPsel, sPsel and BTG levels (all P < 0.001) compared to the untreated state. CONCLUSION. Treatment of uncomplicated essential hypertension using amlodipine-based anti-hypertensive therapy results in a reversal of the platelet morphology abnormalities and indices of platelet activation. This may contribute to a reduction in thrombosis-related complications seen in those whose blood pressure lowering is effective.

AB - BACKGROUND AND AIM. Platelet abnormalities have been described in hypertension, especially in the presence of target organ damage. Our aim was to study the differences in morphology and indices of platelet activation in treatment-naive patients with essential hypertension as compared to normotensive controls and secondly, to study the effects of amlodipine-based antihypertensive therapy on these indices. METHODS. We recruited 42 previously untreated, newly diagnosed hypertensive patients (25 men; mean age 53 years) for the cross-sectional study, where data were compared with those from 30 normotensive controls (20 men; mean age 57 years). Of the 42 untreated hypertensive patients who were recruited, 27 patients successfully completed, the six-month treatment phase with amlodipine-based antihypertensive therapy. Platelet morphology (volume and mass) was quantified, and plasma markers of platelet activation (βTG and sPsel) measured in citrated plasma. The mass of P-selectin in each platelet (pPsel) was determined by lysing a fixed number of platelets and then determining the levels of P-selectin in the lysate. RESULTS. Hypertensive patients had significantly higher platelet volume (P = 0.01) and mass (P = 0.003), plasma βTG and sPsel, and pPsel levels (all P < 0.001) compared to the controls. After a mean treatment time of 6 months, there was a decrease in platelet volume (P < 0.001) and mass (P = 0.02), with lower pPsel, sPsel and BTG levels (all P < 0.001) compared to the untreated state. CONCLUSION. Treatment of uncomplicated essential hypertension using amlodipine-based anti-hypertensive therapy results in a reversal of the platelet morphology abnormalities and indices of platelet activation. This may contribute to a reduction in thrombosis-related complications seen in those whose blood pressure lowering is effective.

KW - Calcium channel blockers

KW - Hypertension

KW - Platelet activation

UR - http://www.scopus.com/inward/record.url?scp=8544282427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544282427&partnerID=8YFLogxK

U2 - 10.1080/07853890410017386

DO - 10.1080/07853890410017386

M3 - Article

C2 - 15513305

AN - SCOPUS:8544282427

VL - 36

SP - 552

EP - 557

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 7

ER -